A Look At Analyst Ratings Summary: CBS Corporation (NYSE:CBS), Colgate-Palmolive Company (NYSE:CL)

CBS Corporation (NYSE:CBS) remained bearish with a decrease -0.82% putting the price on the $54.53 per share in last trading session ended on 7/20/2016. The stock recent traded volume was lower as compared with its average volume of 4007360 shares. The corporation has an earnings per share (EPS) ratio of 3.10. For the next twelve months, the average of individual price target estimates submitted by covering sell-side analysts is $63.00. The company traded as low as $54.27 on the day. The latest trading activity showed that the CBS Corp  price went down -6.34% from its 52-week low and trades up 42.84% versus its 52-week high. It shifted up 8.65% in contrast to its 200 day moving average of $51.99. The current price escalated 0.58% from its SMA 50 of $54.39.

CBS Corporation (NYSE:CBS) Detailed Analyst Recommendation

A number of Reuters analysts recently commented on the stock. Currently the company has earned ‘Buy’ from 13 equity analysts. 1 analysts hold ‘Sell’ rating for the stock. 8 analysts have suggested the company is a ‘Hold’. ‘Underperform’ verdict was shared by 0 analyst and ‘Outperform’ recommendation was issued by 14 analyst. The company has an Average Rating of 1.94 based on analysts tracked by Thomson Reuters.

On 7/20/2016, Colgate-Palmolive Company (NYSE:CL) completed business day lower at $74.12 with -0.07%. The firm exchanged hands at a volume of 2961822. In contrast, the average volume was 3214570 shares. In the past 52 weeks, the equity’s price traded between $49.97 and $ 75.33. The stock has market worth of $66.18B. After the day began at $74.27, the company was seen hitting $74.51 as its intraday high price and $74.09 as its bottom price. The prior close of the stock price is recorded at $74.17.

Colgate-Palmolive Co has moved 2.84% above its 50-day simple moving average of $72.60 and went up 8.90% from its 200-day simple moving average of $69.41. The debt-to-equity ratio (D/E) was recorded at -. The institutional ownership stake in the corporation is 75.40% while the Beta value stands at 0.50. Its RSI (Relative Strength Index) reached 60.45.

Colgate-Palmolive Company (NYSE:CL) Analyst Research Coverage

A number of Wall Street analysts stated their opinion on the stock. Currently the company has earned ‘Buy’ from 2 equity analysts. 0 analysts assign ‘Sell’ rating for the stock. 17 analysts have suggested the company is a ‘Hold’. ‘Underperform’ verdict was shared by 0 analyst and ‘Overweight’ recommendation was issued by 2 analyst. The company has an Average Rating of 2.71 based on Thomson Reuters I/B/E/S scale of 1-5.

Here Are Research Reports Worth Watching: Textron Inc. (NYSE:TXT), Laboratory Corp. of America Holdings (NYSE:LH)

Textron Inc. (NYSE:TXT) remained bullish with an increase +1.45% putting the price on the $39.27 per share in last trading session ended on 7/20/2016. The stock recent traded volume was lower as compared with its average volume of 1706700 shares. The corporation has an earnings per share (EPS) ratio of 2.60. For the next twelve months, the average of individual price target estimates submitted by covering sell-side analysts is $45.42. The company traded as low as $38.60 on the day. The latest trading activity showed that the Textron Inc  price went down -11.47% from its 52-week low and trades up 28.10% versus its 52-week high. It shifted up 2.99% in contrast to its 200 day moving average of $36.70. The current price escalated 3.67% from its SMA 50 of $37.86.

Textron Inc. (NYSE:TXT) Detailed Analyst Recommendation

A number of Reuters analysts recently commented on the stock. Currently the company has earned ‘Buy’ from 4 equity analysts. 0 analysts hold ‘Sell’ rating for the stock. 3 analysts have suggested the company is a ‘Hold’. ‘Underperform’ verdict was shared by 1 analyst and ‘Outperform’ recommendation was issued by 5 analyst. The company has an Average Rating of 2.08 based on analysts tracked by Thomson Reuters.

On 7/20/2016, Laboratory Corp. of America Holdings (NYSE:LH) completed business day higher at $138.12 with +0.96%. The firm exchanged hands at a volume of 1131737. In contrast, the average volume was 946630 shares. In the past 52 weeks, the equity’s price traded between $97.79 and $ 137.48. The stock has market worth of $14.16B. After the day began at $136.98, the company was seen hitting $138.63 as its intraday high price and $136.51 as its bottom price. The prior close of the stock price is recorded at $136.80.

Laboratory Corporation of America Holdings has moved 6.64% above its 50-day simple moving average of $130.99 and went up 15.03% from its 200-day simple moving average of $120.13. The debt-to-equity ratio (D/E) was recorded at 1.24. The institutional ownership stake in the corporation is 95.30% while the Beta value stands at 0.87. Its RSI (Relative Strength Index) reached 72.62.

Laboratory Corp. of America Holdings (NYSE:LH) Analyst Research Coverage

A number of Wall Street analysts stated their opinion on the stock. Currently the company has earned ‘Buy’ from 4 equity analysts. 0 analysts assign ‘Sell’ rating for the stock. 5 analysts have suggested the company is a ‘Hold’. ‘Underperform’ verdict was shared by 0 analyst and ‘Overweight’ recommendation was issued by 10 analyst. The company has an Average Rating of 2.05 based on Thomson Reuters I/B/E/S scale of 1-5.

Notable Stock Analyst Ratings: AFLAC Incorporated (NYSE:AFL), Costco Wholesale Corporation (NASDAQ:COST)

AFLAC Incorporated (NYSE:AFL) remained bullish with an increase +0.33% putting the price on the $73.45 per share in last trading session ended on 7/20/2016. The stock recent traded volume was lower as compared with its average volume of 2149700 shares. The corporation has an earnings per share (EPS) ratio of 6.08. For the next twelve months, the average of individual price target estimates submitted by covering sell-side analysts is $70.77. The company traded as low as $73.30 on the day. The latest trading activity showed that the Aflac Inc  price went down -0.93% from its 52-week low and trades up 45.70% versus its 52-week high. It shifted up 15.81% in contrast to its 200 day moving average of $64.78. The current price escalated 4.82% from its SMA 50 of $70.70.

AFLAC Incorporated (NYSE:AFL) Detailed Analyst Recommendation

A number of Reuters analysts recently commented on the stock. Currently the company has earned ‘Buy’ from 1 equity analysts. 0 analysts hold ‘Sell’ rating for the stock. 13 analysts have suggested the company is a ‘Hold’. ‘Underperform’ verdict was shared by 2 analyst and ‘Outperform’ recommendation was issued by 0 analyst. The company has an Average Rating of 3.00 based on analysts tracked by Thomson Reuters.

On 7/20/2016, Costco Wholesale Corporation (NASDAQ:COST) completed business day lower at $168.04 with -0.05%. The firm exchanged hands at a volume of 1336877. In contrast, the average volume was 2732860 shares. In the past 52 weeks, the equity’s price traded between $116.07 and $ 168.77. The stock has market worth of $73.85B. After the day began at $168.25, the company was seen hitting $168.26 as its intraday high price and $166.95 as its bottom price. The prior close of the stock price is recorded at $168.12.

Costco Wholesale Corp has moved 9.06% above its 50-day simple moving average of $158.36 and went up 9.26% from its 200-day simple moving average of $152.69. The debt-to-equity ratio (D/E) was recorded at 0.44. The institutional ownership stake in the corporation is 74.00% while the Beta value stands at 0.56. Its RSI (Relative Strength Index) reached 78.36.

Costco Wholesale Corporation (NASDAQ:COST) Analyst Research Coverage

A number of Wall Street analysts stated their opinion on the stock. Currently the company has earned ‘Buy’ from 6 equity analysts. 0 analysts assign ‘Sell’ rating for the stock. 10 analysts have suggested the company is a ‘Hold’. ‘Underperform’ verdict was shared by 0 analyst and ‘Overweight’ recommendation was issued by 12 analyst. The company has an Average Rating of 2.14 based on Thomson Reuters I/B/E/S scale of 1-5.

Analyst Ratings Summary To Observe: Dover Corp (NYSE:DOV), Digital Realty Trust, Inc. (NYSE:DLR)

Dover Corp (NYSE:DOV) remained bullish with an increase +0.11% putting the price on the $73.05 per share in last trading session ended on 7/20/2016. The stock recent traded volume was higher as compared with its average volume of 1354740 shares. The corporation has an earnings per share (EPS) ratio of 3.67. For the next twelve months, the average of individual price target estimates submitted by covering sell-side analysts is $70.57. The company traded as low as $72.61 on the day. The latest trading activity showed that the Dover Corp  price went down -0.60% from its 52-week low and trades up 45.42% versus its 52-week high. It shifted up 15.76% in contrast to its 200 day moving average of $64.17. The current price escalated 6.80% from its SMA 50 of $69.94.

Dover Corp (NYSE:DOV) Detailed Analyst Recommendation

A number of Reuters analysts recently commented on the stock. Currently the company has earned ‘Buy’ from 4 equity analysts. 1 analysts hold ‘Sell’ rating for the stock. 11 analysts have suggested the company is a ‘Hold’. ‘Underperform’ verdict was shared by 1 analyst and ‘Outperform’ recommendation was issued by 0 analyst. The company has an Average Rating of 2.71 based on analysts tracked by Thomson Reuters.

On 7/20/2016, Digital Realty Trust, Inc. (NYSE:DLR) completed business day lower at $104.88 with -1.06%. The firm exchanged hands at a volume of 1589505. In contrast, the average volume was 2190540 shares. In the past 52 weeks, the equity’s price traded between $58.41 and $ 113.21. The stock has market worth of $15.47B. After the day began at $106.03, the company was seen hitting $106.50 as its intraday high price and $103.81 as its bottom price. The prior close of the stock price is recorded at $106.00.

Digital Realty Trust Inc has moved 3.86% above its 50-day simple moving average of $104.68 and went up 26.17% from its 200-day simple moving average of $90.06. The debt-to-equity ratio (D/E) was recorded at 1.98. The institutional ownership stake in the corporation is – while the Beta value stands at 0.38. Its RSI (Relative Strength Index) reached 48.68.

Digital Realty Trust, Inc. (NYSE:DLR) Analyst Research Coverage

A number of Wall Street analysts stated their opinion on the stock. Currently the company has earned ‘Buy’ from 4 equity analysts. 2 analysts assign ‘Sell’ rating for the stock. 8 analysts have suggested the company is a ‘Hold’. ‘Underperform’ verdict was shared by 0 analyst and ‘Overweight’ recommendation was issued by 5 analyst. The company has an Average Rating of 2.53 based on Thomson Reuters I/B/E/S scale of 1-5.

Stock Analyst Opinions On Watch List: ServiceNow Inc (NYSE:NOW), Ross Stores, Inc. (NASDAQ:ROST)

ServiceNow Inc (NYSE:NOW) remained bullish with an increase +3.80% putting the price on the $72.65 per share in last trading session ended on 7/20/2016. The stock recent traded volume was higher as compared with its average volume of 1651200 shares. The corporation has an earnings per share (EPS) ratio of -2.95. For the next twelve months, the average of individual price target estimates submitted by covering sell-side analysts is $83.93. The company traded as low as $70.11 on the day. The latest trading activity showed that the ServiceNow Inc  price went down -20.41% from its 52-week low and trades up 57.93% versus its 52-week high. It shifted up 1.29% in contrast to its 200 day moving average of $66.69. The current price escalated 3.08% from its SMA 50 of $70.94.

ServiceNow Inc (NYSE:NOW) Detailed Analyst Recommendation

A number of Reuters analysts recently commented on the stock. Currently the company has earned ‘Buy’ from 14 equity analysts. 0 analysts hold ‘Sell’ rating for the stock. 4 analysts have suggested the company is a ‘Hold’. ‘Underperform’ verdict was shared by 0 analyst and ‘Outperform’ recommendation was issued by 12 analyst. The company has an Average Rating of 1.67 based on analysts tracked by Thomson Reuters.

On 7/20/2016, Ross Stores, Inc. (NASDAQ:ROST) completed business day higher at $59.32 with +0.19%. The firm exchanged hands at a volume of 1751393. In contrast, the average volume was 2930720 shares. In the past 52 weeks, the equity’s price traded between $43.16 and $ 59.53. The stock has market worth of $23.63B. After the day began at $59.22, the company was seen hitting $59.50 as its intraday high price and $59.06 as its bottom price. The prior close of the stock price is recorded at $59.21.

Ross Stores Inc has moved 7.68% above its 50-day simple moving average of $55.54 and went up 9.70% from its 200-day simple moving average of $55.75. The debt-to-equity ratio (D/E) was recorded at 0.16. The institutional ownership stake in the corporation is 91.00% while the Beta value stands at 0.78. Its RSI (Relative Strength Index) reached 79.45.

Ross Stores, Inc. (NASDAQ:ROST) Analyst Research Coverage

A number of Wall Street analysts stated their opinion on the stock. Currently the company has earned ‘Buy’ from 9 equity analysts. 0 analysts assign ‘Sell’ rating for the stock. 11 analysts have suggested the company is a ‘Hold’. ‘Underperform’ verdict was shared by 1 analyst and ‘Overweight’ recommendation was issued by 8 analyst. The company has an Average Rating of 2.14 based on Thomson Reuters I/B/E/S scale of 1-5.

Notable Analyst Views: Allergan plc Ordinary Shares (NYSE:AGN), Hasbro, Inc. (NASDAQ:HAS)

Allergan plc Ordinary Shares (NYSE:AGN) remained bullish with an increase +1.78% putting the price on the $246.95 per share in last trading session ended on 7/20/2016. The stock recent traded volume was lower as compared with its average volume of 3606250 shares. The corporation has an earnings per share (EPS) ratio of -5.63. For the next twelve months, the average of individual price target estimates submitted by covering sell-side analysts is $293.06. The company traded as low as $243.55 on the day. The latest trading activity showed that the Allergan plc  price went down -27.44% from its 52-week low and trades up 26.32% versus its 52-week high. It shifted down -8.31% in contrast to its 200 day moving average of $256.11. The current price escalated 5.21% from its SMA 50 of $238.79.

Allergan plc Ordinary Shares (NYSE:AGN) Detailed Analyst Recommendation

A number of Reuters analysts recently commented on the stock. Currently the company has earned ‘Buy’ from 8 equity analysts. 0 analysts hold ‘Sell’ rating for the stock. 4 analysts have suggested the company is a ‘Hold’. ‘Underperform’ verdict was shared by 0 analyst and ‘Outperform’ recommendation was issued by 7 analyst. The company has an Average Rating of 1.79 based on analysts tracked by Thomson Reuters.

On 7/20/2016, Hasbro, Inc. (NASDAQ:HAS) completed business day higher at $81.33 with +0.31%. The firm exchanged hands at a volume of 2197395. In contrast, the average volume was 1151100 shares. In the past 52 weeks, the equity’s price traded between $59.29 and $ 88.01. The stock has market worth of $10.11B. After the day began at $81.50, the company was seen hitting $81.67 as its intraday high price and $80.73 as its bottom price. The prior close of the stock price is recorded at $81.08.

Hasbro Inc has moved -4.43% below its 50-day simple moving average of $84.71 and went up 5.16% from its 200-day simple moving average of $80.01. The debt-to-equity ratio (D/E) was recorded at 1.02. The institutional ownership stake in the corporation is 82.30% while the Beta value stands at 1.08. Its RSI (Relative Strength Index) reached 40.90.

Hasbro, Inc. (NASDAQ:HAS) Analyst Research Coverage

A number of Wall Street analysts stated their opinion on the stock. Currently the company has earned ‘Buy’ from 2 equity analysts. 0 analysts assign ‘Sell’ rating for the stock. 9 analysts have suggested the company is a ‘Hold’. ‘Underperform’ verdict was shared by 0 analyst and ‘Overweight’ recommendation was issued by 1 analyst. The company has an Average Rating of 2.58 based on Thomson Reuters I/B/E/S scale of 1-5.

Stock Analyst Opinions On Watch List: Boeing Co (NYSE:BA), Paychex, Inc. (NASDAQ:PAYX)

Boeing Co (NYSE:BA) remained bullish with an increase +0.04% putting the price on the $134.72 per share in last trading session ended on 7/20/2016. The stock recent traded volume was lower as compared with its average volume of 4225950 shares. The corporation has an earnings per share (EPS) ratio of 7.40. For the next twelve months, the average of individual price target estimates submitted by covering sell-side analysts is $145.47. The company traded as low as $134.04 on the day. The latest trading activity showed that the Boeing Co  price went down -8.97% from its 52-week low and trades up 33.03% versus its 52-week high. It shifted up 2.57% in contrast to its 200 day moving average of $127.63. The current price escalated 3.58% from its SMA 50 of $130.05.

Boeing Co (NYSE:BA) Detailed Analyst Recommendation

A number of Reuters analysts recently commented on the stock. Currently the company has earned ‘Buy’ from 5 equity analysts. 0 analysts hold ‘Sell’ rating for the stock. 9 analysts have suggested the company is a ‘Hold’. ‘Underperform’ verdict was shared by 2 analyst and ‘Outperform’ recommendation was issued by 5 analyst. The company has an Average Rating of 2.38 based on analysts tracked by Thomson Reuters.

On 7/20/2016, Paychex, Inc. (NASDAQ:PAYX) completed business day lower at $60.51 with -0.31%. The firm exchanged hands at a volume of 2618674. In contrast, the average volume was 2150980 shares. In the past 52 weeks, the equity’s price traded between $40.56 and $ 61.87. The stock has market worth of $21.86B. After the day began at $60.62, the company was seen hitting $60.72 as its intraday high price and $60.28 as its bottom price. The prior close of the stock price is recorded at $60.70.

Paychex Inc has moved 8.66% above its 50-day simple moving average of $57.26 and went up 16.12% from its 200-day simple moving average of $52.83. The debt-to-equity ratio (D/E) was recorded at 0.00. The institutional ownership stake in the corporation is 70.70% while the Beta value stands at 0.83. Its RSI (Relative Strength Index) reached 69.45.

Paychex, Inc. (NASDAQ:PAYX) Analyst Research Coverage

A number of Wall Street analysts stated their opinion on the stock. Currently the company has earned ‘Buy’ from 2 equity analysts. 3 analysts assign ‘Sell’ rating for the stock. 10 analysts have suggested the company is a ‘Hold’. ‘Underperform’ verdict was shared by 4 analyst and ‘Overweight’ recommendation was issued by 0 analyst. The company has an Average Rating of 3.32 based on Thomson Reuters I/B/E/S scale of 1-5.

Analysts Upgrade of the Day: T2 Biosystems Inc (NASDAQ:TTOO)

T2 Biosystems Inc (NASDAQ:TTOO) received a stock rating upgrade from WBB Securities on Jul-20-16. In a note to investors, the firm issued a Strong Buy rating and hiked the target price on the stock from $11 to $12. The analysts previously had a Buy rating on the stock.

Analysts have a consensus target price of $10.57 in the 12-month period. The price objective is 95.02% higher than the recent closing price of $5.42. The 52-week price range is $4.92-$16.61 and the company has a market capitalization of $133.93 billion. Analysts covering the shares maintain a consensus Strong Buy rating, according to Zacks Investment Research. Zero analyst has rated the stock with a sell rating, 2 has assigned a hold rating, 1 says it’s a buy, and 3 have assigned a strong buy rating to the company.

On July 18, 2016 T2 Biosystems Inc (TTOO), a company developing innovative diagnostic products to improve patient health, has signed a multi-year agreement to provide T2 Biosystems’ T2 Magnetic Resonance technology platform, or T2MR, for Bayer’s research and development efforts in blood coagulation disorders. This collaboration will develop tools and evaluate assays to help drive drug discovery and biomarker research for select Bayer hemostasis-related programs.

The sensitivity of T2MR in blood coagulation (hemostasis) research allows for the rapid and comprehensive monitoring of drug side effects in animal models and patients.

“We are very enthusiastic about our collaboration with Bayer and the important validation it represents for our T2MR technology in the field of hemostasis,” said John McDonough, chief executive officer of T2 Biosystems. “Together with Bayer, we look forward to continuing the exploration of the clinical potential of our platform to provide improved patient care in this area of significant unmet need.”

The companies have been working together for the last year and recently extended the collaboration to include a number of pre-clinical and early clinical programs. This collaboration will enable T2 Biosystems and Bayer to evaluate the T2MR technology with the hemostasis drug discovery and development efforts at Bayer.

T2MR is a diagnostic detection method utilizing miniaturized magnetic resonance technology that measures how water molecules react in the presence of magnetic fields. The T2MR technology platform offers a fast, simple and sensitive alternative to existing diagnostic methodologies. T2MR technology powers all of the diagnostic innovation at T2 Biosystems and enables the detection of a variety of different targets including molecular targets, immunodiagnostics and a broad range of hemostasis measurements. Additionally, by incorporating the T2MR diagnostic platform into clinical trials, drug developers have the potential to dramatically enrich patient populations, which could result in decreased timelines and reduced cost of trials. Another key benefit to drug developers is the potential to have patients diagnosed rapidly enough to avoid courses of empiric therapy prior to the administration of the investigational drug, which could help to achieve clinical superiority.

What Analysts say about United Financial Bancorp Inc (NASDAQ:UBNK)

United Financial Bancorp Inc (NASDAQ:UBNK) received a stock rating downgrade from Hovde Group on Jul-20-16. In a note to investors, the firm issued a Market Perform rating. The analysts previously had an Outperform rating on the stock.

Analysts have a consensus target price of $13.50 in the 12-month period. The price objective is 2.20% higher than the recent closing price of $13.21. The 52-week price range is $10.08-$13.85 and the company has a market capitalization of $662.22 billion. Analysts covering the shares maintain a consensus Buy rating, according to Zacks Investment Research. Zero analyst has rated the stock with a sell rating, 1 has assigned a hold rating, 0 says it’s a buy, and 1 have assigned a strong buy rating to the company.

United Financial Bancorp Inc (UBNK) on July 19, 2016 announced results for the quarter ended June 30, 2016.

The Company had net income of $9.1 million, or $0.18 per diluted share, for the quarter ended June 30, 2016, compared to net income for the linked quarter of $11.9 million, or $0.24 per diluted share. Operating net income (Non-GAAP) for the second quarter of 2016 was $10.0 million, or $0.20 per diluted share, compared to $10.9 million, or $0.22 per diluted share for the linked quarter. Operating net income for the second quarter of 2016 is adjusted for purchase accounting impacts, net gain from sales of securities and the effect of position eliminations as a result of the Company’s previously disclosed reorganization plan. Additionally, in the first quarter of 2016, operating income was also adjusted for Federal Home Loan Bank of Boston (“FHLBB”) prepayment penalties. The Company reported net income of $13.3 million, or $0.27 per diluted share, for the quarter ended June 30, 2015.

“In the second quarter of 2016, operating revenue increased 2%, but operating net income declined to $0.20 per diluted share from $0.22 per diluted share for the linked quarter. Despite record low interest rates, our operating net interest margin declined only one basis point and we maintained strong expense discipline evidenced in our ratio of operating non-interest expense to average assets at 2.08%. Management remains focused on its previously disclosed four key objectives to enhance shareholder value in this difficult operating environment for banks. Tangible book value per share increased to $10.39 from $10.20 after paying a dividend of $0.12 per share. Asset quality remains strong and non-interest bearing deposits increased by 10% year over year,” stated William H. W.  Crawford, IV, Chief Executive Officer of the Company and the Bank. “In addition, I want to thank our talented employees for their continued steadfast focus on serving our customers and communities.”

Analysts: Galena Biopharma, Inc. (NASDAQ:GALE) stock is worth $2.47

Galena Biopharma, Inc. (NASDAQ:GALE) up 18.41 per cent in the past week, is under coverage of 4 analysts who collectively recommend a hold rating on stock. 2 of the analysts have a buy or better rating; the 0 sells versus 0 underperforms. The 3 equity analysts who rate the stock have an average target price at $2.47, with individual targets ranging between $0.4 and $5. The shares closed last trade at $0.49, implying that analysts see shares rising about 404.08 per cent in 12 months’ time.

Insider Activity: Insiders look pessimistic about the prospects of the company that they seem to offload shares while they are -66.97 down so far this year. A Former CFO at Galena Biopharma, Inc. (GALE) sold shares in the company in a transaction completed on Wednesday June 01, 2016. Dunlap Ryan offloaded 126,875 shares in the company at an average price of $2.18 and ended up generating $276,590 in proceeds. Dunlap Ryan retains 18,702 shares in the company after this transaction. A Director in the company, Chin Richard, on Wednesday February 12, 2014 collected $811,880 from the sale of 187,500 shares at $2.18 each. Insiders are expected to know better about the health and prospects of their company, which is why insiders’ move deserves attention.

Earnings Roundup: In the last fiscal quarter alone, Galena Biopharma, Inc. generated around $0 in revenue and net income. For the prior quarter revenue for the company hit $1.44M, with earnings at -$0.12/share.

Galena Biopharma, Inc. (GALE) Analyst Coverage

Raymond James has been a brokerage house following shares of Galena Biopharma, Inc. (GALE), so its rating change is noteworthy. The stock was downgraded to Mkt Perform from Outperform, wrote analysts at Raymond James, in a note issued to clients on Wednesday June 29, 2016. There was another key note issued by Oppenheimer on Thursday November 12, 2015. The firm lifted its rating on GALE from Perform to Outperform.

Price Momentum: Despite the 27.76% increase in value, the stock’s new closing price represents a -80.5% fall in value from company’s one year high of $2.49. The stock is currently holding above its 50 day moving average of $-66.66 and below its 200 day moving average of $1.41. Over the last three months and over the last six months, the shares of Galena Biopharma, Inc. (GALE), have changed -63.23% and 1.19%, respectively.